Trinity Current Deferred Revenue from 2010 to 2024

TRIB Stock  USD 1.82  0.01  0.55%   
Trinity Biotech's Current Deferred Revenue is decreasing over the years with stable fluctuation. Current Deferred Revenue is expected to dwindle to about 265.1 K. Current Deferred Revenue is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. View All Fundamentals
 
Current Deferred Revenue  
First Reported
2001-12-31
Previous Quarter
114 K
Current Value
279 K
Quarterly Volatility
2.3 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Trinity Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Trinity main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Total Revenue of 78.6 M or Gross Profit of 35 M, as well as many exotic indicators such as Price To Sales Ratio of 0.055, Dividend Yield of 0.0062 or Days Sales Outstanding of 95.59. Trinity financial statements analysis is a perfect complement when working with Trinity Biotech Valuation or Volatility modules.
  
This module can also supplement Trinity Biotech's financial leverage analysis and stock options assessment as well as various Trinity Biotech Technical models . Check out the analysis of Trinity Biotech Correlation against competitors.

Latest Trinity Biotech's Current Deferred Revenue Growth Pattern

Below is the plot of the Current Deferred Revenue of Trinity Biotech plc over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Trinity Biotech's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Trinity Biotech's overall financial position and show how it may be relating to other accounts over time.
Current Deferred Revenue10 Years Trend
Pretty Stable
   Current Deferred Revenue   
       Timeline  

Trinity Current Deferred Revenue Regression Statistics

Arithmetic Mean876,471
Geometric Mean329,344
Coefficient Of Variation198.07
Mean Deviation1,127,743
Median250,000
Standard Deviation1,736,040
Sample Variance3T
Range5.7M
R-Value(0.24)
Mean Square Error3.1T
R-Squared0.06
Significance0.39
Slope(92,828)
Total Sum of Squares42.2T

Trinity Current Deferred Revenue History

2024265.1 K
2023279 K
2022114 K
2021141 K
20204.4 M
2019292 K
2018312 K

About Trinity Biotech Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Trinity Biotech income statement, its balance sheet, and the statement of cash flows. Trinity Biotech investors use historical funamental indicators, such as Trinity Biotech's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Trinity Biotech investors may use each financial statement separately, they are all related. The changes in Trinity Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Trinity Biotech's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Trinity Biotech Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Trinity Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue279 K265.1 K
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Trinity Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Trinity Biotech's short interest history, or implied volatility extrapolated from Trinity Biotech options trading.

Currently Active Assets on Macroaxis

When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:
Check out the analysis of Trinity Biotech Correlation against competitors.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.

Complementary Tools for Trinity Stock analysis

When running Trinity Biotech's price analysis, check to measure Trinity Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Biotech is operating at the current time. Most of Trinity Biotech's value examination focuses on studying past and present price action to predict the probability of Trinity Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trinity Biotech's price. Additionally, you may evaluate how the addition of Trinity Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Stocks Directory
Find actively traded stocks across global markets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Is Trinity Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Earnings Share
(4.96)
Revenue Per Share
7.424
Quarterly Revenue Growth
(0.26)
Return On Assets
(0.13)
The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.